DNA
NYSEGinkgo Bioworks Holdings Inc.
Price$7.70-0.64 (-7.73%)
01:30 PM07:45 PM
News · 26 weeks40+100%
2025-10-262026-04-19
Mix2190d
- Insider8(38%)
- SEC Filings6(29%)
- Other5(24%)
- Earnings2(10%)
Latest news
25 items- INSIDERSEC Form 4 filed by Coen Steven P.4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
- INSIDERSEC Form 4 filed by Coen Steven P.4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
- INSIDERSEC Form 4 filed by Canton Barry4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
- INSIDERSEC Form 4 filed by Shetty Reshma P.4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
- INSIDERSEC Form 4 filed by Shetty Reshma P.4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
- INSIDERSEC Form 4 filed by Canton Barry4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
- INSIDERSEC Form 4 filed by Kelly Jason R4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
- SECGinkgo Bioworks Holdings Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits8-K - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Ginkgo Bioworks Holdings Inc.SCHEDULE 13G/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)
- INSIDERSEC Form 4 filed by Ginkgo Bioworks Holdings Inc.4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
- SECSEC Form 144 filed by Ginkgo Bioworks Holdings Inc.144 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)
- PRGinkgo Bioworks Launches Ginkgo Cloud Lab, Powered by Autonomous Lab InfrastructureBOSTON, March 2, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE:DNA) today announced the official launch of Ginkgo Cloud Lab. This new interface allows researchers to transition their benchwork to Ginkgo's autonomous lab infrastructure directly through a web browser. Ginkgo Cloud Lab runs on the company's proprietary Reconfigurable Automation Carts (RACs). These modular units combine high-precision robotic arms, maglev sample transport tracks, and industrial-grade software to create an endlessly flexible laboratory environment.The Cloud Lab provides remote access to a fleet of over
- SECGinkgo Bioworks Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)
- SECSEC Form S-8 filed by Ginkgo Bioworks Holdings Inc.S-8 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)
- SECSEC Form 10-K filed by Ginkgo Bioworks Holdings Inc.10-K - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)
- SECGinkgo Bioworks Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)
- PRGinkgo Bioworks Reports Fourth Quarter and Full Year 2025 Financial Results, Announces Focus on Autonomous Labs Offerings and Divestiture of its Non-Core Biosecurity BusinessGinkgo provides an update on its fourth quarter financial resultsBOSTON, Feb. 26, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )) today announced its results for the fourth quarter and full year ended December 31, 2025. The update, including a webcast slide presentation with additional details on the third quarter, as well as supplemental financial information will be available at investors.ginkgobioworks.com. Fourth Quarter 2025 Financial ResultsFourth quarter 2025 Total revenue of $33 million compared to $44 million in the comparable prior year pe
- PRGinkgo Bioworks Announces Date of Fourth Quarter and Full Year 2025 Results PresentationPresentation and Q&A session scheduled for post-market on Thursday, February 26, 2026BOSTON, Feb. 19, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )) today announced that it plans to host a presentation and Q&A session reviewing business performance for the fourth quarter and full year ended December 31, 2025, on Thursday, February 26, 2026, beginning at 4:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com, and a replay will be made available.To ask a
- PRGinkgo Bioworks and Invaio Sciences Enter Collaboration to Develop Manufacturing Technology for Peptide-based Agricultural ProductsCollaboration aims to develop a commercialization-ready microorganism to manufacture next-generation peptide crop solutions at grower-friendly costsBOSTON, Feb. 18, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE:DNA, ", Ginkgo", )) and Invaio Sciences, an agricultural biotechnology company leading in nature-positive crop protection solutions, today announced a collaboration to develop strains that can efficiently manufacture peptide-based crop protection inputs. Growers are seeking inputs that protect agricultural crops from pests that are increasingly resistant to conventional chem
- PRGinkgo Bioworks' Autonomous Laboratory Driven by OpenAI's GPT-5 Achieves 40% Improvement Over State-of-the-Art Scientific BenchmarkResearch conducted in collaboration with OpenAI using Ginkgo's cloud laboratoryPreprint describes how GPT-5-driven autonomous lab significantly reduced reaction costs in cell-free protein synthesisGPT-5-driven autonomous lab executed over 36,000 experimentsGinkgo now selling the AI-improved reaction mix in its reagents store, showing commercial potential of AI-driven scienceBOSTON, Feb. 5, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE:DNA) today announced it has demonstrated, in collaboration with OpenAI, an AI system that autonomously designed, executed, and learned from biological experiments with minimal human involvement. In a new preprint, the company reports the system reduced cell-free p
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Ginkgo Bioworks Holdings Inc.SCHEDULE 13G/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)
- INSIDEROfficer Coen Steven P. converted options into 1,805 shares and sold $8,667 worth of shares (972 units at $8.92), increasing direct ownership by 11% to 8,321 units (SEC Form 4)4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
- PRGinkgo Bioworks Announces Participation in the 44th Annual J.P. Morgan Healthcare ConferenceBOSTON, Jan. 13, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE:DNA) announced today that Co-Founder and CEO Jason Kelly is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026 at 10:30 a.m. PT (1:30 p.m. ET). Further details, including slides, will be posted on the company's investor relations website at https://investors.ginkgobioworks.com/events. About Ginkgo Bioworks Ginkgo Bioworks builds the tools that make biology easier to engineer for everyone. Ginkgo R&D Solutions delivers customizable R&D packages—such as protein engine
- SECGinkgo Bioworks Holdings Inc. filed SEC Form 8-K: Leadership Update, Other Events8-K - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)
- PRGinkgo Bioworks Partners with Carnegie-Mellon University to Develop Innovative New Cancer Screening ApproachBOSTON, Dec. 22, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE:DNA) today announced its partnership with Carnegie-Mellon University (CMU) for an award by the Advanced Research Projects Agency for Health (ARPA-H) for its POSEIDON program (Platform Optimizing SynBio for Early Intervention and Detection in Oncology). With Ginkgo Bioworks serving as the Commercial Partner, the project will also be led by Rebecca Taylor (principal investigator), professor of mechanical engineering at Carnegie Mellon University. Combining recent advancements in synthetic biology with cutting-edge dete